Literature DB >> 31248720

Autoimmune pancreatitis not otherwise specified (NOS): Clinical features and outcomes of the forgotten type.

Nicolò de Pretis1, Filippo Vieceli2, Alessandro Brandolese2, Lorenzo Brozzi2, Antonio Amodio2, Luca Frulloni2.   

Abstract

BACKGROUND: Autoimmune pancreatitis (AIP) is a well-recognized fibroinflammatory disease of the pancreas. Despite the significant number of studies published on AIP type 1 and 2, no studies have been focused on AIP type not otherwise specified (NOS) and therefore very little is known about clinical features and long-term outcomes of these patients. The aim of this study was to investigate clinical and radiological features of AIP type NOS-patients.
METHODS: Patients classified as AIP type NOS at clinical onset included in our database prospectively maintained since 1995 were evaluated. Epidemiological, clinical data were collected and analyzed.
RESULTS: Forty-six patients were included in the study. The clinical onset was mainly characterized by weight loss, jaundice and acute pancreatitis. Eight patients (17.4%) were reclassified as AIP type 2 during follow-up because of the development of ulcerative colitis. Seven patients (15.2%) experienced relapse after steroid treatment but only one (2.2%) needed immunosuppressive drugs because of recurrent relapses.
CONCLUSIONS: AIP type NOS shares clinical features similar to AIP type 2 and a relevant proportion of patients was reclassified as AIP type 2 during follow-up because of the development of ulcerative colitis. The risk of relapse is low but not irrelevant.
Copyright © 2019 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmune pancreatitis; Follow-up; Not otherwise specified; Outcome; Therapy

Mesh:

Substances:

Year:  2019        PMID: 31248720     DOI: 10.1016/j.hbpd.2019.05.010

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  4 in total

Review 1.  IgG4-related disease: Changing epidemiology and new thoughts on a multisystem disease.

Authors:  Annarosa Floreani; Kazuichi Okazaki; Kazushige Uchida; M Eric Gershwin
Journal:  J Transl Autoimmun       Date:  2020-12-19

2.  The features and clinical outcomes of inflammatory bowel disease associated with autoimmune pancreatitis: A greater awareness is needed.

Authors:  Maria Cristina Conti Bellocchi; Eugenio Marconato; Laura Lamonaca; Martina Cattani Mottes; Rachele Ciccocioppo; Silvia Carrara; Nicolo' de Pretis; Armando Gabbrielli; Stefano Francesco Crinò; Luca Frulloni
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

Review 3.  Type 2 Autoimmune Pancreatitis: Consensus and Controversies.

Authors:  Yoh Zen
Journal:  Gut Liver       Date:  2022-05-15       Impact factor: 4.519

4.  Unraveling the relationship between autoimmune pancreatitis type 2 and inflammatory bowel disease: Results from two centers and systematic review of the literature.

Authors:  Sara Nikolic; Marco Lanzillotta; Nikola Panic; Torkel B Brismar; Carlos Fernández Moro; Gabriele Capurso; Emanuel Della Torre; J-Matthias Löhr; Miroslav Vujasinovic
Journal:  United European Gastroenterol J       Date:  2022-05-08       Impact factor: 6.866

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.